Angiodynamics (ANGO) Depreciation & Amortization (CF) (2010 - 2026)

Angiodynamics' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $5.6 million for Q2 2026.

• Quarterly Depreciation & Amortization (CF) fell 4.05% year-over-year to $5.6 million in Q2 2026, while the trailing twelve-month figure through May 2026 was $23.0 million (down 11.03% YoY) and the FY2026 annual result came in at $23.0 million, down 11.03% from the prior year.
• Depreciation & Amortization (CF) was $5.6 million for Q2 2026 at Angiodynamics, roughly flat from $5.6 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $7.8 million in Q1 2023 and bottomed at $5.6 million in Q1 2026.
• A 5-year average of $6.8 million and a median of $6.8 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) climbed 17.52% — and 2025, when it fell 16.26%.
• Angiodynamics' Depreciation & Amortization (CF) stood at $7.8 million in 2022, then declined by 14.49% to $6.7 million in 2023, then rose by 2.66% to $6.9 million in 2024, then declined by 16.26% to $5.7 million in 2025, then declined by 2.61% to $5.6 million in 2026.
• Business Quant data shows ANGO's Depreciation & Amortization (CF) at $5.6 million in Q2 2026, $5.6 million in Q1 2026, and $5.7 million in Q4 2025.